CBX2 and breast carcinoma: For example, Papadakis et al. [30] confirmed that mRNA BAG-1 acts as a biomarker in early breast cancer prognosis, Zheng et al. [31] found that CBX2 is a potential prognostic biomarker and therapeutic target for breast cancer.